Corbus Pharmaceuticals
CRBP
69 hedge funds and large institutions have $109M invested in Corbus Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 11 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
9% more capital invested
Capital invested by funds: $101M → $109M (+$8.69M)
0% more funds holding
Funds holding: 69 → 69 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0.05% less ownership
Funds ownership: 1.06% → 1.01% (-0.05%)
34% less call options, than puts
Call options by funds: $1.58M | Put options by funds: $2.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
| 2 |
Millennium Management
New York
|
+$1.04M |
| 3 |
BlackRock
New York
|
+$919K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$577K |
| 5 |
State Street
Boston,
Massachusetts
|
+$503K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.33M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.19M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.11M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$820K |
| 5 |
AG
Artal Group
Luxembourg
|
-$652K |
CRBP Hedge Fund Activity: Q3 2017 in Review
69 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2017, worth a combined $109M — up 8.6% from $101M a quarter earlier.
Fund positioning in CRBP was balanced in Q3 2017: 11 funds opened new positions, 11 closed out, 27 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was Perceptive Advisors, cutting an estimated $5.33M.
- 69 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $109M of Corbus Pharmaceuticals stock for Q3 2017, up 8.6% quarter-over-quarter.
- 11 funds opened new Corbus Pharmaceuticals positions in Q3 2017 and 11 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2017 was Vanguard Group, an estimated $1.04M added.
- The largest Corbus Pharmaceuticals seller in Q3 2017 was Perceptive Advisors, an estimated $5.33M sold.
Based on aggregated 13F filings for Q3 2017.